R

Ryazan Regional Clinical Hospital | Acute Cardiac Care Department

Research site
(Unclaimed)
Location
Ryazan, Street International, 3-a, Ryazan, Ryazan, Russian Federation

Site insights

Top conditions

Top treatments

Daratumumab
Bendamustine
Idelalisib
Ibrutinib
Cusatuzumab
GS-1101
Azacitidine
Obinutuzumab
Guselkumab
Zanubrutinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 20 total trials

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Drug: Ibrutinib

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Venetoclax

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Cusatuzumab
Drug: Azacitidine

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma bene...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Daratumumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion-dependent participants with low or intermediate-1 risk...

Active, not recruiting
Myelodysplastic Syndromes
Drug: Imetelstat
Drug: Placebo

Trial sponsors

J
Gilead Sciences logo
Amgen logo
Astex Pharmaceuticals logo
BeiGene logo
CTI BioPharma logo
Ferring logo
G
O
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems